

Editorial



Journal of Lipid and Atherosclerosis Update 2025

OPEN ACCESS

Received: Jan 9, 2025

Accepted: Jan 13, 2025

Published online: Jan 18, 2025

Correspondence to

In-Kyung Jeong

Division of Endocrinology and Metabolism,
Department of Internal Medicine, Kyung Hee
University Hospital at Gangdong, Kyung Hee
University School of Medicine, 892 Dongnam-
ro, Gangdong-gu, Seoul 05278, Korea.
Email: jik1016@naver.com
jik1016@khu.ac.kr

© 2025 The Korean Society of Lipid and
Atherosclerosis.

This is an Open Access article distributed
under the terms of the Creative Commons
Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>)
which permits unrestricted non-commercial
use, distribution, and reproduction in any
medium, provided the original work is properly
cited.

ORCID iDs

Ji Hye Heo <https://orcid.org/0000-0001-5445-8007>
In-Kyung Jeong <https://orcid.org/0000-0001-7857-546X>

Funding

None.

Conflict of Interest

In-Kyung Jeong is Editor-in-Chief and Ji Hye Heo is Deputy Editor of the *Journal of Lipid and Atherosclerosis* since 2025. However, they were not involved in the peer reviewer selection, evaluation, or decision-making process of this article. No other potential

Ji Hye Heo ,¹ In-Kyung Jeong ²

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea

²Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea

As the editorial team of the *Journal of Lipid and Atherosclerosis (JLA)*, we are pleased to present our latest journal metrics, which reflect the dedication and collaboration of our authors, reviewers, and readers.

Since *JLA* is indexed in PubMed in 2019 and in Scopus in 2020, the journal has grown to publish more than 30 high-quality reviews, original articles, brief reports, letters to the editor, and editorials in 2024.

This growth is reflected in the steady rise of citations, culminating in an estimated impact factor of 5.35 in Clarivate's Journal Citation Reports (JCR) as of December 31, 2024. This places *JLA* in the first quartile (Q1) for Cardiology and Cardiovascular Medicine and Internal Medicine categories, and the second quartile (Q2) for Endocrinology, Diabetes & Metabolism, based on the JCR 2023 comparison.

The journal's CiteScore Tracker for 2024, as calculated by Scopus (accessible at: <https://www.scopus.com/sourceid/21101032315>), has shown a notable improvement, reaching 7.6 by December 5, 2024 (765 citations across 101 documents). This marks a significant leap from its previous CiteScores of 5.1 in 2022 and 6.5 in 2023. The total number of citations has dramatically increased in 2024, from 107 in 2023 to 246 in 2024. The 2 most frequently cited articles addressed important topics, including understanding and utilizing claim data¹ and a novel methodology approach for systematic reviews in the field of atherosclerosis research.² Moreover, the publication of diverse and recently highlighted studies covering various topics related to atherosclerosis³⁻⁵ has significantly contributed to the recent surge in the *JLA*'s citation index, with these articles being widely cited across multiple disciplines.

While the impact factor remains an imperfect metric, it is nonetheless a widely recognized measure of a journal's influence. The editorial board acknowledges its limitations but views this upward trend as a positive signal, likely to attract even higher-quality submissions in the future. The board is committed to further enhancing *JLA*'s impact factor, broadening its influence in the research and clinical communities, and strengthening its position as a leading journal in this field.

In 2025, we aim to further elevate our journal's value by strengthening its esteemed reputation through active collaboration with the Korean Society of Lipid and Atherosclerosis

conflicts of interest relevant to this article were reported.

Data Availability Statement

Not Applicable.

Author Contributions

Writing - original draft: Heo JH, Jeong IK;

Writing - review & editing: Jeong IK.

and leading opinion groups. Key initiatives include optimizing the submission process for user convenience, shortening timelines from submission to publication, and enhancing editorial and review capacity by recruiting expert board members worldwide. Transparency will be improved by updating policies on data sharing, preprints, artificial intelligence disclosures, and peer review. Additionally, increased use of graphical abstracts and article-focused promotional videos will further enhance the journal's visibility and citation metrics.

As *JLA* continues to evolve, we encourage you to join us in this journey. Consider submitting your research, contributing as a reviewer, or sharing your insights to further our shared mission. Should you have any questions or comments, please contact us at staff@e-jla.org. Together, we look forward to another year of advancing excellence in lipid and atherosclerosis research.

REFERENCES

1. Kyoung DS, Kim HS. Understanding and utilizing claim data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) database for research. *J Lipid Atheroscler* 2022;11:103-110. [PUBMED](#) | [CROSSREF](#)
2. Choi GJ, Kang H. Introduction to umbrella reviews as a useful evidence-based practice. *J Lipid Atheroscler* 2023;12:3-11. [PUBMED](#) | [CROSSREF](#)
3. Cho YK, Lee YL, Jung CH. The cardiovascular effect of tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist. *J Lipid Atheroscler* 2023;12:213-222. [PUBMED](#) | [CROSSREF](#)
4. Saucedo-Orozco H, Voorrips SN, Yurista SR, de Boer RA, Westenbrink BD. SGLT2 inhibitors and ketone metabolism in heart failure. *J Lipid Atheroscler* 2022;11:1-19. [PUBMED](#) | [CROSSREF](#)
5. Tarkhishvili A, Koentges C, Pfeil K, Gollmer J, Byrne NJ, Vosko I, et al. Effects of short term adiponectin receptor agonism on cardiac function and energetics in diabetic *db/db* mice. *J Lipid Atheroscler* 2022;11:161-177. [PUBMED](#) | [CROSSREF](#)